Posts Tagged ‘Pharmaceuticals’

Syndax Pharmaceuticals Raises $6 Million in Securities Offering

Syndax Pharmaceuticals Raises $6 Million in Securities Offering
WALTHAM, Mass., Aug. 11 /PRNewswire/ — Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life …

Read more on redOrbit

Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing …

Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing …
KNOXVILLE, Tenn.—-Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC to license its TruPoints® strategic partnering platform.

Read more on Business Wire via Yahoo! Finance

Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …

Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

Read more on PharmaceuticalOnline

Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.

Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
TUSTIN, CA–(Marketwire – 07/13/10) – Radient Pharmaceuticals Corporation (RPC) (AMEX: RPC – News ) announced today that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc. (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines. Radient Pharmaceuticals intends to acquire PDI, in a stock …

Read more on Marketwire via Yahoo! Finance

Sunesis Pharmaceuticals Reports First Quarter 2010 Financial Results

Sunesis Pharmaceuticals Reports First Quarter 2010 Financial Results
SOUTH SAN FRANCISCO, CA–(Marketwire – April 29, 2010) – Sunesis Pharmaceuticals, Inc. ( NASDAQ : SNSS ) today reported financial results for the first quarter ended March 31, 2010. Net loss was $4.6 million for the first quarter of 2010. As of March 31, 2010, Sunesis had cash and cash equivalents of $14.7 million.

Read more on Marketwire

Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals

Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
SALT LAKE CITY — Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals .

Read more on GlobeNewswire via Yahoo! Finance

NIAID funds second study of Aeolus Pharmaceuticals’ AEOL 10150 as potential countermeasure to GI-ARS

NIAID funds second study of Aeolus Pharmaceuticals’ AEOL 10150 as potential countermeasure to GI-ARS
Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

Read more on News-Medical-Net

Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI …

Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI …
MISSION VIEJO, Calif.—-Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health’s , National Institute of Allergy and Infectious Diseases Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal tract.

Read more on Business Wire via Yahoo! Finance

Strong demand despite macroeconomic conditions leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

Strong demand despite macroeconomic conditions leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals
IMS Health today reported 5.1 percent growth in 2009 U.S. sales of ethical pharmaceuticals and insulins through retail and non-retail channels, reaching $300.3 billion, compared with growth of 1.8 percent in 2008.

Read more on News-Medical-Net

Cyclacel Pharmaceuticals Announces Multiple Abstracts Selected for Presentation at American Association for Cancer …

Cyclacel Pharmaceuticals Announces Multiple Abstracts Selected for Presentation at American Association for Cancer …
BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. today announced that six abstracts highlighting translational and preclinical data for Cyclacel’s cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

Read more on GlobeNewswire via Yahoo! Finance